Rate of clinical progression in Parkinson's disease. A prospective study

被引:131
作者
Schrag, Anette [1 ]
Dodel, Richard
Spottke, Annika
Bornschein, Bernhard
Siebert, Uwe
Quinn, Niall P.
机构
[1] UCL, Dept Clin Neurosci, Royal Free Hosp, London NW3 2PF, England
[2] UCL, Dept Motor Neurosci & Movement Disorders, Inst Neurol, London, England
[3] Univ Marburg, Dept Neurol, Marburg, Germany
[4] UMIT Univ Hlth Sci Med Informat & Technol, Hall, Germany
[5] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Inst Technol Assessment, Boston, MA USA
[6] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA
关键词
Parkinson's disease; progression; UPDRS; scales;
D O I
10.1002/mds.21429
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Few prospective data on the clinical progression of Parkinson's disease (PD) in patient groups outside treatment trials in selected patients are available, and controversy exists on the rate of clinical disease progression with advancing disease. In this study, we investigated the rate of clinical progression of PD in a clinic-based sample of 145 patients over 1 year and in a community-based sample of 124 patients over 4 years. Depending on the sample and clinical scale used, mean deterioration of motor and disability scores ranged from 2.4 to 7.4% of the maximum possible score per year, and standard deviations indicated that there was considerable variability of progression rates between individuals. The progression of motor scores decreased with follow-up over 4 years and significantly decreased in more advanced disease stages. Deterioration of disability scores did not differ between disease stages; this may reflect the increasing rate of disease complications, which contribute to increasing disability in addition to motor impairment alone, in more advanced disease. Thus, motor fluctuations, hallucinations, depression, memory problems, and bladder symptoms were all reported more often at follow-up in the community-based sample (all P < 0.01), and dyskinesias, motor fluctuations, falls, and hallucinations were more common and cognitive and depression scores worse in higher disease stages in the clinic-based sample (all P < 0.001). We conclude that progression of motor scores in PD decreases with advancing disease in PD. However, disability continues to deteriorate with advancing disease and with the development of disease complications that are likely to be related to additional extrastriatal pathology. (C) 2007 Movement Disorder Society.
引用
收藏
页码:938 / 945
页数:8
相关论文
共 50 条
[31]   Plasma glial fibrillary acidic protein as a biomarker of disease progression in Parkinson's disease: a prospective cohort study [J].
Lin, Junyu ;
Ou, Ruwei ;
Li, Chunyu ;
Hou, Yanbing ;
Zhang, Lingyu ;
Wei, Qianqian ;
Pang, Dejiang ;
Liu, Kuncheng ;
Jiang, Qirui ;
Yang, Tianmi ;
Xiao, Yi ;
Zhao, Bi ;
Chen, Xueping ;
Song, Wei ;
Yang, Jing ;
Wu, Ying ;
Shang, Huifang .
BMC MEDICINE, 2023, 21 (01)
[32]   Protection against Parkinson's disease progression: Clinical experience [J].
LeWittt, Peter A. ;
Taylor, Danette C. .
NEUROTHERAPEUTICS, 2008, 5 (02) :210-225
[33]   Protection against Parkinson’s disease progression: Clinical experience [J].
Peter A. LeWitt ;
Danette C. Taylor .
Neurotherapeutics, 2008, 5 :210-225
[34]   The association of motor reserve and clinical progression in Parkinson's disease [J].
Bai, Xueqin ;
Zhang, Shiwei ;
Li, Qiuyue ;
Guo, Tao ;
Guan, Xiaojun ;
Qian, Andan ;
Chen, Shuangli ;
Zhou, Ronghui ;
Cheng, Yitong ;
Chen, Haoxin ;
Gou, Zhaoke ;
Xie, Chenglong ;
Wang, Zhen ;
Zhang, Minming ;
Zheng, Xiangwu ;
Wang, Meihao .
NEUROIMAGE-CLINICAL, 2024, 44
[35]   Sequence of clinical and neurodegeneration events in Parkinson's disease progression [J].
Oxtoby, Neil P. ;
Leyland, Louise-Ann ;
Aksman, Leon M. ;
Thomas, George E. C. ;
Bunting, Emma L. ;
Wijeratne, Peter A. ;
Young, Alexandra L. ;
Zarkali, Angelika ;
Tan, Manuela M. X. ;
Bremner, Fion D. ;
Keane, Pearse A. ;
Morris, Huw R. ;
Schrag, Anette E. ;
Alexander, Daniel C. ;
Weil, Rimona S. .
BRAIN, 2021, 144 (03) :975-988
[36]   Imaging nigral pathology and clinical progression in Parkinson's disease [J].
Du, Guangwei ;
Lewis, Mechelle M. ;
Sen, Suman ;
Wang, Jianli ;
Shaffer, Michele L. ;
Styner, Martin ;
Yang, Qing X. ;
Huang, Xuemei .
MOVEMENT DISORDERS, 2012, 27 (13) :1636-1643
[37]   Prevalence of cerebrovascular lesions in Parkinson's disease. A postmortem study [J].
Kurt A. Jellinger .
Acta Neuropathologica, 2003, 105 :415-419
[38]   Prevalence of cerebrovascular lesions in Parkinson's disease. A postmortem study [J].
Jellinger, KA .
ACTA NEUROPATHOLOGICA, 2003, 105 (05) :415-419
[39]   The effect of donepezil on dementia in Parkinson's disease and Alzheimer's disease.: A pilot study [J].
Rektorová, I .
CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2004, 67 (05) :359-+
[40]   Progression of motor symptoms in Parkinson's disease [J].
Xia, Ruiping ;
Mao, Zhi-Hong .
NEUROSCIENCE BULLETIN, 2012, 28 (01) :39-48